FAQ: NRx Pharmaceuticals Presentation at Noble Capital Markets Conference

What is the main announcement in this press release?

NRx Pharmaceuticals announced that CEO Dr. Jonathan Javitt will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025, to discuss their low-dose D-Cycloserine product and expanded clinical operations.

When and where is the presentation taking place?

The presentation is scheduled for October 8, 2025, at 9:30 a.m. ET at the Noble Capital Markets Emerging Growth Virtual Equity Conference.

Who is presenting on behalf of NRx Pharmaceuticals?

Dr. Jonathan Javitt, the Founder, Chairman, and CEO of NRx Pharmaceuticals, will be presenting at the conference.

What specific products and treatments will be discussed?

Dr. Javitt will discuss the upcoming launch of a low-dose D-Cycloserine product that enhances Transcranial Magnetic Stimulation effectiveness for depression, as well as NRX-100 (IV ketamine) and NRX-101 (oral D-cycloserine/lurasidone) for treating central nervous system disorders.

What are NRx Pharmaceuticals’ key therapeutic focus areas?

The company focuses on developing therapeutics for central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD using their NMDA platform.

What regulatory designations has NRx received for their products?

NRX-100 has Fast Track Designation for treating Suicidal Ideation in Depression, and NRX-101 has Breakthrough Therapy Designation for treating suicidal bipolar depression.

What recent regulatory filings has NRx made?

NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for treating suicidal depression.

What collaborations and expansions are mentioned?

The company is expanding clinical operations in Florida and collaborating with the U.S. Department of Veterans Affairs to treat veterans with suicidal depression and PTSD.

Where can I find more detailed information about this announcement?

The full press release can be viewed at https://ibn.fm/KRCWz, and more information about the company is available at www.nrxpharma.com.

What is the significance of this presentation for investors?

This presentation provides investors with updates on NRx’s product pipeline, regulatory progress, clinical expansions, and collaborations, offering insights into the company’s growth strategy and future prospects in treating serious mental health conditions.